Panitumumab Ineffective in G13D KRAS Mutant Colorectal Cancer

Phase III trial results suggest that therapies targeting the epidermal growth factor receptor should be limited to patients with KRAS wild-type tumors.

Monoclonal antibodies that target the epidermal growth factor receptor (EGFR) improve response rate, progression free survival (PFS), and, in some studies, overall survival (OS) in patients with wild-type KRAS metastatic colorectal cancer (mCRC). Benefit from EGFR antibody therapy seems to be limited to patients with wild-type KRAS tumors, but recent data suggest that the anti-EGFR agent cetuximab might be effective for mCRC patients with KRAS G13D mutations (JW Oncol Hematol Jan 11 2011).

Now, investigators have analyzed three large phase III trials that evaluated the effect of adding the anti-EGFR agent panitumumab to best supportive care or to chemotherapy with either FOLFOX4 (fluorouracil, leucovorin, and oxaliplatin) or FOLFIRI (fluorou…

Reviewing Author

David H. Ilson, MD, PhD

Disclosures

Consultant/Advisory BoardAstraZeneca; Merck; Taiho; Astellas; Bristol Myers Squibb; Regeneron; Oncolys; Amgen; Daiichi Sankyo

David H. Ilson, MD, PhD

Disclosures

Consultant/Advisory BoardAstraZeneca; Merck; Taiho; Astellas; Bristol Myers Squibb; Regeneron; Oncolys; Amgen; Daiichi Sankyo